Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Nitto to invest $225 million in oligonucleotides

by Michael McCoy
April 9, 2021 | A version of this story appeared in Volume 99, Issue 13

 

Nitto Denko plans to spend about $225 million to increase capacity in its oligonucleotide contract manufacturing business by early 2023. The Japanese firm says it will expand process and analytical development at the unit’s headquarters in Milford, Massachusetts. Nitto also says it will construct a new building and oligo production line. Future plans include spending a similar amount to expand capacity for the polymer support needed to make oligos.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.